nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonordefrin—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.0577	0.406	CbGeAlD
Levonordefrin—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.0312	0.0405	CbGpPWpGaD
Levonordefrin—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.0216	0.0281	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0214	0.0279	CbGpPWpGaD
Levonordefrin—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0206	0.0267	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.02	0.026	CbGpPWpGaD
Levonordefrin—ADRA2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0183	0.0238	CbGpPWpGaD
Levonordefrin—ADRA2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0178	0.0231	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0175	0.0228	CbGpPWpGaD
Levonordefrin—ADRA2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0171	0.0222	CbGpPWpGaD
Levonordefrin—ADRA2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0166	0.0216	CbGpPWpGaD
Levonordefrin—ADRA2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0165	0.0215	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0163	0.0211	CbGpPWpGaD
Levonordefrin—ADRA2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0154	0.0201	CbGpPWpGaD
Levonordefrin—ADRA2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0154	0.02	CbGpPWpGaD
Levonordefrin—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0149	0.0194	CbGpPWpGaD
Levonordefrin—ADRA2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0149	0.0194	CbGpPWpGaD
Levonordefrin—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0145	0.0188	CbGpPWpGaD
Levonordefrin—ADRA2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0144	0.0187	CbGpPWpGaD
Levonordefrin—ADRA2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0139	0.0181	CbGpPWpGaD
Levonordefrin—ADRA2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0139	0.0181	CbGpPWpGaD
Levonordefrin—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0139	0.018	CbGpPWpGaD
Levonordefrin—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0135	0.0176	CbGpPWpGaD
Levonordefrin—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0135	0.0175	CbGpPWpGaD
Levonordefrin—ADRA2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.013	0.0169	CbGpPWpGaD
Levonordefrin—Phenylpropanolamine—SLC6A3—Gilles de la Tourette syndrome	0.0129	0.146	CrCbGaD
Levonordefrin—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0126	0.0163	CbGpPWpGaD
Levonordefrin—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0125	0.0163	CbGpPWpGaD
Levonordefrin—L-DOPA—DRD4—Gilles de la Tourette syndrome	0.0124	0.14	CrCbGaD
Levonordefrin—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0122	0.0158	CbGpPWpGaD
Levonordefrin—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0117	0.0152	CbGpPWpGaD
Levonordefrin—ADRA2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0116	0.0151	CbGpPWpGaD
Levonordefrin—Dopamine—DRD4—Gilles de la Tourette syndrome	0.0116	0.131	CrCbGaD
Levonordefrin—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0114	0.0148	CbGpPWpGaD
Levonordefrin—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0113	0.0147	CbGpPWpGaD
Levonordefrin—ADRA2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0108	0.0141	CbGpPWpGaD
Levonordefrin—L-DOPA—DRD3—Gilles de la Tourette syndrome	0.0107	0.121	CrCbGaD
Levonordefrin—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0105	0.0137	CbGpPWpGaD
Levonordefrin—Dopamine—DRD3—Gilles de la Tourette syndrome	0.00996	0.113	CrCbGaD
Levonordefrin—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00974	0.0127	CbGpPWpGaD
Levonordefrin—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00946	0.0123	CbGpPWpGaD
Levonordefrin—Dopamine—SLC6A3—Gilles de la Tourette syndrome	0.00927	0.105	CrCbGaD
Levonordefrin—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0091	0.0118	CbGpPWpGaD
Levonordefrin—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00879	0.0114	CbGpPWpGaD
Levonordefrin—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00846	0.011	CbGpPWpGaD
Levonordefrin—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00795	0.0103	CbGpPWpGaD
Levonordefrin—ADRA2C—midbrain—Gilles de la Tourette syndrome	0.00787	0.0554	CbGeAlD
Levonordefrin—L-DOPA—DRD2—Gilles de la Tourette syndrome	0.00742	0.0838	CrCbGaD
Levonordefrin—Norepinephrine—DRD2—Gilles de la Tourette syndrome	0.00742	0.0838	CrCbGaD
Levonordefrin—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00739	0.0096	CbGpPWpGaD
Levonordefrin—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00731	0.0514	CbGeAlD
Levonordefrin—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.00703	0.0495	CbGeAlD
Levonordefrin—Dopamine—DRD2—Gilles de la Tourette syndrome	0.0069	0.0779	CrCbGaD
Levonordefrin—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00679	0.0478	CbGeAlD
Levonordefrin—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.00654	0.046	CbGeAlD
Levonordefrin—ADRA2C—nervous system—Gilles de la Tourette syndrome	0.00647	0.0455	CbGeAlD
Levonordefrin—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.00628	0.0442	CbGeAlD
Levonordefrin—ADRA2C—central nervous system—Gilles de la Tourette syndrome	0.00623	0.0438	CbGeAlD
Levonordefrin—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.0061	0.00793	CbGpPWpGaD
Levonordefrin—SLC6A2—brain—Gilles de la Tourette syndrome	0.00558	0.0393	CbGeAlD
Levonordefrin—ADRA1A—brain—Gilles de la Tourette syndrome	0.00519	0.0365	CbGeAlD
Levonordefrin—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00516	0.0363	CbGeAlD
Levonordefrin—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00497	0.035	CbGeAlD
Levonordefrin—ADRA2C—brain—Gilles de la Tourette syndrome	0.00495	0.0348	CbGeAlD
Levonordefrin—ADRA2A—brain—Gilles de la Tourette syndrome	0.00395	0.0278	CbGeAlD
Levonordefrin—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00385	0.005	CbGpPWpGaD
Levonordefrin—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0038	0.00494	CbGpPWpGaD
Levonordefrin—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00369	0.0048	CbGpPWpGaD
Levonordefrin—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00355	0.00462	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00353	0.00459	CbGpPWpGaD
Levonordefrin—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00345	0.00448	CbGpPWpGaD
Levonordefrin—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00344	0.00447	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00343	0.00445	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0033	0.00429	CbGpPWpGaD
Levonordefrin—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00321	0.00418	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0032	0.00416	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00319	0.00415	CbGpPWpGaD
Levonordefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00302	0.00393	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00298	0.00388	CbGpPWpGaD
Levonordefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00294	0.00382	CbGpPWpGaD
Levonordefrin—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00289	0.00375	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00288	0.00375	CbGpPWpGaD
Levonordefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00282	0.00367	CbGpPWpGaD
Levonordefrin—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0028	0.00364	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0028	0.00364	CbGpPWpGaD
Levonordefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00274	0.00356	CbGpPWpGaD
Levonordefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00273	0.00355	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00268	0.00348	CbGpPWpGaD
Levonordefrin—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00261	0.00339	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00261	0.00339	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0026	0.00338	CbGpPWpGaD
Levonordefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00255	0.00332	CbGpPWpGaD
Levonordefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00247	0.00321	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00242	0.00315	CbGpPWpGaD
Levonordefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0024	0.00312	CbGpPWpGaD
Levonordefrin—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00236	0.00307	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0023	0.00299	CbGpPWpGaD
Levonordefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00229	0.00298	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00224	0.00291	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00224	0.00291	CbGpPWpGaD
Levonordefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00223	0.0029	CbGpPWpGaD
Levonordefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00223	0.00289	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00215	0.0028	CbGpPWpGaD
Levonordefrin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00211	0.00275	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00209	0.00271	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00209	0.00271	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00208	0.00271	CbGpPWpGaD
Levonordefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00207	0.0027	CbGpPWpGaD
Levonordefrin—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.00206	0.00268	CbGpPWpGaD
Levonordefrin—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00195	0.00254	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00195	0.00253	CbGpPWpGaD
Levonordefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00192	0.00249	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00188	0.00244	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00183	0.00237	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00183	0.00237	CbGpPWpGaD
Levonordefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00179	0.00233	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00175	0.00227	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0017	0.00221	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0017	0.0022	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0017	0.0022	CbGpPWpGaD
Levonordefrin—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.00168	0.00218	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00158	0.00205	CbGpPWpGaD
Levonordefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00156	0.00203	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00146	0.0019	CbGpPWpGaD
Levonordefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00145	0.00189	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00136	0.00177	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0013	0.00169	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00126	0.00164	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00122	0.00158	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00119	0.00155	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00118	0.00154	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00118	0.00153	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00118	0.00153	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00115	0.00149	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00111	0.00144	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0011	0.00143	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0011	0.00143	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00107	0.00139	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00107	0.00139	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00106	0.00138	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00103	0.00134	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000998	0.0013	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000987	0.00128	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000965	0.00125	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000961	0.00125	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000958	0.00125	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000937	0.00122	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000897	0.00117	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000893	0.00116	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000873	0.00113	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00087	0.00113	CbGpPWpGaD
Levonordefrin—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000824	0.00107	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000811	0.00105	CbGpPWpGaD
Levonordefrin—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00077	0.001	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000748	0.000973	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000699	0.000909	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000698	0.000907	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000678	0.000881	CbGpPWpGaD
Levonordefrin—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000673	0.000875	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000652	0.000848	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000633	0.000823	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000631	0.000821	CbGpPWpGaD
Levonordefrin—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000625	0.000813	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000611	0.000794	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00059	0.000766	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00057	0.000741	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000568	0.000738	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000553	0.000719	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00053	0.000688	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000515	0.00067	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000514	0.000668	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000479	0.000623	CbGpPWpGaD
Levonordefrin—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000442	0.000575	CbGpPWpGaD
Levonordefrin—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000413	0.000537	CbGpPWpGaD
Levonordefrin—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000361	0.000469	CbGpPWpGaD
Levonordefrin—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000335	0.000436	CbGpPWpGaD
